register

News & Trends - Pharmaceuticals

Government grapples with shingles vaccine rollout fiasco

Health Industry Hub | February 5, 2024 |

Pharma News: In the wake of significant delays in the initial stages of the $800 million rollout of the Shingrix vaccine, General Practitioners (GPs) across the nation find themselves delivering unfortunate news to eager patients facing treatment accessibility issues.

Despite the challenges, Chief Medical Officer Professor Paul Kelly expressed enthusiasm for the high demand witnessed during the first three months of the $800 million program. With over 487,000 doses administered, Professor Kelly reassured the public that the government is dedicated to ensuring timely access to this crucial shingles vaccine.

Acknowledging the current difficulties faced by some individuals in accessing the vaccine due to overwhelming demand, Professor Kelly assured the public that ample doses of Shingrix are ready for administration nationwide, with an additional 100,000 doses set to be distributed in the coming fortnight.

“The Government is also working closely with the vaccine supplier, GSK, to explore options to bring forward additional deliveries of Shingrix into Australia,” said Dr Kelly.

Changes to the National Immunization Program, implemented on November 1st of the previous year, saw Shingrix replace Zostavax, a process that requires time and coordination with state and territory health departments for nationwide distribution.

According to the Australian Institute of Health and Welfare, one in three people will develop shingles in their lifetime, and 20% of those will suffer severe nerve pain which can become permanent.

Highlighting the importance of the shingles vaccination program, Minister Mark Butler, Federal Health and Aged Care, referred to the virus as a “very serious public health menace” during the launch of the free vaccine. Hospital operators echoed this sentiment, emphasising the increasing frequency of shingles-related issues among older Australians in medical facilities.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) […]

More


News & Trends - Pharmaceuticals

Is the imposed PBS funding cap driving the migraine medicines shortage?

Is the imposed PBS funding cap driving the migraine medicines shortage?

Health Industry Hub | February 23, 2024 |

Pharma News: Australia finds itself grappling with an unparalleled shortage of migraine prevention medicines, leaving a significant impact on the […]

More


News & Trends - Pharmaceuticals

MSAC rejects Janssen's CAR T therapy despite clinical superiority, citing need for 'substantial price reduction'

MSAC rejects Janssen’s CAR T therapy despite clinical superiority, citing need for ‘substantial price reduction’

Health Industry Hub | February 23, 2024 |

Pharma News: The Medical Services Advisory Committee (MSAC) has deferred its decision on whether Janssen’s CAR T-cell therapy Carvykti (cilta-cel) […]

More


News & Trends - Pharmaceuticals

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Health Industry Hub | February 23, 2024 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted approval for the first endometriosis treatment in 13 years. Gedeon Richter […]

More


This content is copyright protected. Please subscribe to gain access.